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Background and Objective. Acute leukemia patients
may develop life-threatening gut complications after
intensive chemotherapy. We evaluated the role of
abdominal and pelvic ultrasound (US) examination in
early detection of these complications.
Design and Methods. A cohort of twenty adult acute
leukemia patients undergoing intensive chemothera-
py for remission induction entered the study. All
chemotherapy regimens included cytarabine by con-
tinuous i.v. infusion for several days. 
Results. Three patients had severe gut complica-
tions: 2 cases of enterocolitis and 1 case of gall blad-
der overdistension in the absence of calculi. In all
cases the abnormality was documented by US exam-
ination: US scan showed thickening of the intestinal
wall (two cases), and gall bladder overdistension with
biliary sludge (one case). Immediate medical care
included bowel rest, a broad-spectrum antibiotic,
antimycotic treatment, and granulocyte colony-stim-
ulating factor. All patients recovered from the com-
plication.
Interpretation and Conclusions. We believe that the
favorable outcome obtained in our small series can be
attributed to early diagnosis followed by appropriate
treatment. Early recognition by US and immediate
medical management can lead to complete recovery
of severe intestinal complications in patients with
acute leukemia undergoing intensive chemotherapy. 
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The intensive chemotherapy regimens used fortreating patients with acute leukemia mayinduce several types of gastro-intestinal dam-
age, including necrosis of mucosal epithelial cells,
bacterial invasion, infarction and occasionally per-
foration.1,2 Nausea, vomiting, abdominal pain and
distension, diarrhea, ileus and fever are the most fre-
quent symptoms in these patients.1 Unfortunately, in
most cases the clinical presentation is puzzling and
the correct diagnosis is not immediately suspected.
We investigated adult acute leukemia patients
undergoing intensive chemotherapy, with the aim of
evaluating diagnosis, clinical management and out-
come of these potentially fatal complications.
Design and Methods
From September 1996 to April 1998 we studied 20
consecutive adult patients (12 males and 8 females)
with acute leukemia admitted to hospital to receive
intensive chemotherapy for remission induction. Their
mean age was 44 years (range 25-58). Seventeen had
acute myeloid leukemia and received an induction
regimen according to the EORTC-GIMEMA AML 10
protocol [containing either idarubicin or mitox-
antrone or daunorubicin in combination with etopo-
side and cytarabine (Ara-C) by continuous i.v. infu-
sion]. Three patients had acute lymphoblastic
leukemia and received the GIMEMA ALL 0394 pro-
tocol induction regimen (Ara-C by continuous i.v.
infusion over 7 days, etoposide and idarubicin). At
the time of chemotherapy, all patients had a central
venous line inserted, all received similar bacterial and
fungal prophylaxis (ciprofloxacin and fluconazole)
and none received pre-emptive total parenteral nutri-
tion (TPN). In all patients we evaluated the occur-
rence of severe gastro-intestinal symptoms according
to WHO recommendations. Physical examination,
laboratory tests, blood and stool cultures and toxin
assay for C. difficile were performed in all patients with
gastro-intestinal symptoms. An abdominal and pelvic
ultrasound (US) examination, using portable equip-
ment at the patient's bedside, was carried out by a
hematologist trained in medical ultrasonography
within the first 12 hours of the appearance of symp-
toms and on subsequent days. US was meant to mon-
itor changes in intestinal wall thickness, formation of
intraparietal microabscesses, intestinal pneumatosis
and intraperitoneal effusion.
Results
Of the 20 patients studied, 3 (15%) developed
severe gut complications: 2 cases of enterocolitis and
1 case of gall bladder overdistension without calculi
(Table 1). Clinical manifestations were high grade
fever, right abdominal pain, abdominal distension
and tympany; patients #1 and #2 also had diarrhea
223Ultrasound scan and post-chemotherapy gut complications in AL
and melena. Fever and right abdominal pain appeared
before the other manifestations. The symptoms start-
ed during profound neutropenia, between the twelfth
and the sixteenth day after the start of chemotherapy.
In all cases the diagnosis of severe gut complication
was defined by US scan. The main findings were mod-
erate wall thickening (between 5 and 7 mm) of termi-
nal ileal loops (patients #1 and #2) (Figure 1), and a
distended gall bladder containing sludge, but without
wall thickening (patient #3) (Figure 2). In patient #1
computer axial tomography confirmed the US find-
ings. Only patient #3 had a microbiologically docu-
mented infection (Staphylococcus aureus and Streptococ-
cus mitis grown from blood culture). Stool cultures for
toxin-producing C. difficile were negative in all patients.
All patients were immediately managed with bowel
rest (nasogastric suction and TPN), vigorous broad-
spectrum antibiotic treatment (including specific anti-
anaerobic drugs), empirical systemic antimycotic
treatment and granulocyte colony-stimulating factor
(G-CSF) administration. During this treatment, US fol-
low-up documented improvement of the intestinal
damage. All patients responded to medical manage-
ment without requiring a surgical intervention and sur-
vived. In all patients the resolution of fever and of
abdominal symptoms coincided with the resolution
of neutropenia. 
Discussion
While in relapsed or resistant leukemia patients the
pathogenesis of gastro-intestinal complications may
Table 1. Clinical characteristics and outcome of patients with severe gut complications after induction chemotherapy.
Pt. Sex, age Basic Intestinal Abdominal US finding Medical Complication
disease complication symptoms management outcome
1 F, 26 AML (M4) enterocolitis fever, right lower terminal ileal loop wall thickening meropenem 3 g/daily, recovery
quadrant pain, distension, (about 6 mm),  ileal loop amikacin 1 g/daily,
diarrhea with melena, superdistension with reduction teicoplanin 200 mg/daily, 
vomiting of peristaltic activity, amphotericin-B 50 mg/daily,
moderate ascites metronidazole 1,5 g/daily, 
G-CSF 300 µg/daily, TPN,
nasogastric suction
2 M, 50 AML (M3) enterocolitis fever, abdominal pain,  wall thickening of meropenem 3 g/daily, recovery
distension, diarrhea  ileal loop (about 7 mm) amikacin 1 g/daily, 
with melena, vomiting and proximal colon, teicoplanin 200 mg/daily, 
overdistension, reduced fluconazole 300 mg/daily,
peristaltic activity, moderate ascites metronidazole 1.5 g/daily,
G-CSF 300 µg/daily, TPN, 
nasogastric suction
3 F, 58 ALL (L2) gall bladder fever, abdominal overdistension of gall bladder, ceftazidime 6 g/daily, recovery
overdistension pain, distension, containing biliary sludge, amikacin 1 g/daily, 
without calculi vomiting pericholecystic effusion, positive US vancomycin 2 g/daily,
Murphy's sign fluconazole 300 mg/daily,
G-CSF 300 µg/daily,
nasogastric suction
ALL= acute lymphoblastic leukemia, AML= acute myeloid leukemia, US= ultrasound scan, G-CSF= granulocyte colony-stimulating factor, TPN= total parenteral nutrition.
Figure 1. US scan of patient #2 showing overdistended
ileum (A) and proximal colon wall thickening (B).
be multifactorial (repeated chemotherapy courses,
prolonged periods of profound neutropenia, broad-
spectrum parenteral antibiotic treatments and
intestinal leukemic infiltration),1,2 in patients receiv-
ing a first course of chemotherapy for remission
induction the main mechanism is drug-induced
epithelial toxicity followed by local infection. The
dosage and the modality of administration of Ara-C
seem to be crucial in the development of acute gut
complications.3,4 In particular, continuous i.v. infu-
sion of Ara-C over 7 to 10 days has become popular
in the most recent regimens; thus acute gut compli-
cations are an emerging problem. Enterocolitis and
acute cholecystitis in the absence of calculi are severe
complications during the aplastic phase, with a
reported mortality from 50% to 100%.3,5 The man-
agement is controversial, and therapeutic approach-
es vary from early surgical intervention to only sup-
portive treatment.3,5 Rapid recognition of these com-
plications seems to be crucial for patient survival. 
Our small study shows that early use of abdominal
and pelvic US may be valuable for rapid detection of
severe gut complications.6,7 Proper antibiotic and sup-
portive treatment associated with close US follow-
up3,8,9 are effective methods for avoiding surgical inter-
vention, which is extremely risky in aplastic patients.9
The failure of medical management of similar cases
reported by other authors2,4 is probably related to
delayed diagnosis; indeed, the reported patients had
advanced intestinal damage, as demonstrated by the
findings of ileal wall thickening > 9 mm, intestinal
pneumatosis, perforation and peritonitis.
Since neutrophil recovery is a pivotal event for the
resolution of such complications,8 we suggest early
use of G-CSF and/or of white blood cell transfusions
from G-CSF-treated donors, as has been suggested for
other neutropenia-related severe complications.10-12
Proper studies should also be carried out to test
whether oral glutamine supplementation is effective
in preventing chemotherapy-induced gastro-intesti-
nal damage.13,14
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